- Home
- SNSE vs CRIS Comparison
SNSE vs CRIS Comparison
Compare SNSE & CRIS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SNSE | CRIS |
|---|---|---|
| Founded | 2005 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.9M | 12.9M |
| IPO Year | 2021 | 2000 |
Fundamental Metrics
Financial Performance| Metric | SNSE | CRIS |
|---|---|---|
| Price | $9.75 | $0.92 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 2 |
| Target Price | ★ $72.50 | $16.50 |
| AVG Volume (30 Days) | 88.4K | ★ 1.2M |
| Earning Date | 11-14-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $11,650,000.00 |
| Revenue This Year | N/A | $6.13 |
| Revenue Next Year | N/A | $7.86 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 13.56 |
| 52 Week Low | $5.00 | $0.77 |
| 52 Week High | $18.35 | $3.57 |
Technical Indicators
Market Signals| Indicator | SNSE | CRIS |
|---|---|---|
| Relative Strength Index (RSI) | 49.76 | 41.83 |
| Support Level | $9.32 | $0.87 |
| Resistance Level | $11.51 | $0.98 |
| Average True Range (ATR) | 1.06 | 0.09 |
| MACD | -0.13 | 0.01 |
| Stochastic Oscillator | 33.33 | 54.72 |
Price Performance
Historical ComparisonAbout SNSE Sensei Biotherapeutics Inc.
Sensei Biotherapeutics Inc is an immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients. Its TMAb (Tumor Microenvironment Activated Biologics) platform developing selective therapeutics designed to disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment. The company have four investigational product candidates in various stages of development: SNS-101 (VISTA), SNS-102 (VSIG4 ), SNS-103 (ENTPDase/CD39), SNS-201 (VISTAxCD28).
About CRIS Curis Inc.
Curis Inc is a biotechnology company that develops and commercializes drugs and therapies in the immuno-oncology and precision oncology therapeutic areas. The company targets solid tumors, diffuse large B-cell lymphoma, solid tumors or lymphomas, hematological cancers, and others. Its pipeline products include Fimepinostat, CA-170, CA-4948, CA-327, and Erivedge.